Bionomics Limited (NASDAQ:BNOX) Short Interest Up 101.9% in November

Posted by Charles Blunt on Nov 30th, 2024

Bionomics Limited (NASDAQ:BNOX – Get Free Report) saw a significant increase in short interest during the month of November. As of November 15th, there was short interest totalling 384,300 shares, an increase of 101.9% from the October 31st total of 190,300 shares. Based on an average daily trading volume, of 9,290,000 shares, the days-to-cover ratio is currently 0.0 days.

Institutional Trading of Bionomics

A hedge fund recently bought a new stake in Bionomics stock. Armistice Capital LLC bought a new position in shares of Bionomics Limited (NASDAQ:BNOX – Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 1,226,759 shares of the company’s stock, valued at approximately $941,000. Armistice Capital LLC owned about 15.03% of Bionomics as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 15.90% of the company’s stock.

Bionomics Price Performance

BNOX stock remained flat at $0.30 on Friday. The company had a trading volume of 266,144 shares, compared to its average volume of 2,968,708. The company has a fifty day moving average of $0.33 and a two-hundred day moving average of $0.59. Bionomics has a 52-week low of $0.18 and a 52-week high of $1.60.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. William Blair reiterated an “outperform” rating on shares of Bionomics in a research note on Friday, November 15th. HC Wainwright restated a “buy” rating and set a $8.00 price target on shares of Bionomics in a research note on Thursday, August 1st.

Get Our Latest Report on Bionomics

About Bionomics

(Get Free Report)

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder.